Nanomed lifetime is an important aspect of delivery potential, scientists say

Nanomachines, those tiny programmable particles that have shown in tests to deliver drugs successfully, are now part of an ongoing study at Columbia University designed to discover their degradation over time. This factor is especially important in the delivery field, giving drugs a leg up as they bring treatments where they need to be.


Microneedle patch maker Zosano Pharma raises $50M in IPO

Drug delivery specialist Zosano Pharma raised $50 million in its IPO Tuesday. It sold 4.5 million shares. The stock ended the day up 2 cents from its initial price of $11. The company is primarily known for its lead product, a transdermal treatment for severe osteoporosis delivering the drug teriparatide, now in Phase III. 

PARI snags FDA approval for cystic fibrosis nebulizer platform

Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme.

PhytoTech debuts on Australian stock exchange and will use funds for medical marijuana patch

Australia's PhytoTech Medical last week became the country's first medical marijuana company to first be listed on the country's Australian Securities Exchange, where it raised AUS $5.9 million ($4.7 million) in support of its single-use vaporizer to administer medical marijuana at a precise dosage.

Shire's intrathecally delivered candidate for Hunter syndrome gets FDA's Fast Track Designation

Rare disease specialist Shire announced today that it has received Fast Track Designation from the FDA for a reformulated, intrathecally delivered version of its successful drug for Hunter syndrome, Elaprase.

Australian team developing novel formulation to deliver common diabetes drug

Researchers at Curtin University's Biotechnology and Drug Development Research Laboratory in Perth, Australia, are developing a microcapsule formulation that they say improves the drug delivery and absorption of diabetes drugs.

AbbVie, Unilife enter into drug delivery partnership

AbbVie selected Unilife as its drug delivery partner. AbbVie paid $5 million to enter into the development and supply agreement.

Celator's delivery platform results in FDA's fast-track designation for its cancer candidate

Celator Pharmaceuticals received fast-track designation for its candidate for the treatment of secondary acute myeloid leukemia in elderly patients. CPX-351 is designed to achieve sustained release of the anticancer drugs cytarabine and daunorubicin in a precise ratio.

U. Arizona team looks to bring GI delivery vehicle to market

Researchers have developed and are looking to commercialize a drug delivery system designed to treat inflammation and ulcerations in the colon. The "molecular truck" delivers the drug 5-aminosalicylic acid to the colon, where it can treat diseases such as ulcerative colitis and Crohn's.

'Micromotors' made of zinc and polymer actively release drugs at stomach lining

Tiny polymer tubes coated with zinc may one day be able to treat stomach conditions such as ulcers by acting as "micromotors" carrying drugs to the stomach lining. Animal studies at the University of California, San Diego, demonstrated in vivo that the synthetic motors enhanced the efficiency of drug delivery to the stomach.

India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates

India's Piramal Enterprises made official its intention to purchase Kentucky's Coldstream Laboratories, for $30.6 million, a move that will push the company further into the contract manufacturing of drug delivery components like sterile injectable products, lyophilized (freeze-dried) parenterals, and antibody drug conjugates.

BD must still pay $350M+ due to safety syringe spat; other punishments delayed pending appeal

A federal court has upheld the $350 million-plus in damages that Becton Dickinson owes Retractactable Technologies due to a legal spat over drug-delivering prefilled syringes. But the court stayed a previous order requiring the company to inform end users about its false advertising regarding the syringes.

Intersect ENT announces prelim Q4 financials at JPM, defining goals for its drug-loaded stents

Sinusitis implant maker Intersect ENT took the stage at the JP Morgan Healthcare Conference in San Francisco this week to announce preliminary financial results from the fourth quarter of 2014, its first full quarter since its July IPO worth $63.3 million.

Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline

RNAi specialist Tekmira Pharmaceuticals expanded its reach with the announcement of the purchase of OnCore Biopharma, developer of an all-oral candidate for hepatitis B, saying that a combination therapy approach is the optimal way to treat that disease.

Pill-maker Capsugel collects Australian uni's tech for greater bioavailability

New Jersey capsule technology specialist Capsugel has picked up a drug delivery platform developed at Australia's Monash University that makes use of lipidlike counter-ion salts to improve the bioavailability of certain drugs.

Extended-release drugs to face extra scrutiny from FDA's new Office of Pharmaceutical Quality

"Modified release is a high-risk area, so we're going to put a lot of emphasis on it," said the deputy director of the FDA's new Office of Pharmaceutical Quality, Lawrence Yu, during a press conference describing the new division.

Alnylam and Isis strengthen RNAi alliance, agree to swap IP

Alnylam and Isis Pharmaceuticals announced an intellectual property cross-licensing agreement that they hope will leave them both better equipped to deal with the challenges of developing the first commercial RNAi therapy, including utilization of the promising but still-unproven RNA interference drug delivery pathway, and sometimes jittery investors.

FDA approves AbbVie's Parkinson's drug, featuring delivery straight into the GI tract

The FDA just approved AbbVie's novel formulation of the standard Parkinson's drugs carbidopa and levodopa, Duopa, which is delivered straight into the patient's small intestine over 16 consecutive hours using an infusion pump and procedurally placed tube.

Palo Alto pain management startup Carbylan vies for $86M IPO

Biotech startup Carbylan Therapeutics is looking to raise $86 million in an IPO to support its injectable osteoarthritis pain treatment, which is currently in Phase III with another late-stage trial on the way in mid-2015.

Blend Therapeutics receives $21M in Series B round

Blend Therapeutics announced that it has received $21 million in new financing via a Series B venture round, as well as debt financing from an institutional investment firm to advance its Pentarin biologic drug conjugates.